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THE EFFECT OF PULSED ELECTROMAGNETIC FIELDS ON
PHYSICAL FUNCTION MEASURED BY WOMAC
OSTEOARTHRITIS INDEX IN PATIENTS WITH KNEE
OSTEOARTHRITIS -A PILOT STUDY
T. Nemcic, S. Grazio, F. Grubisic, V. Matijevic, H. Skala
Sestre Milosrdnice Univ. Hosp., Zagreb, Croatia
Purpose: The aim of our study was to asses the effect of pulsed
electromagnetic ﬁelds (PEMFs) on physical function measured by
Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) in patients with knee osteoarthritis (OA) through a
single-blind placebo controlled clinical study.
Methods: Fifty-six consecutive patients, aged 60.62±8.81 years,
presenting to Outpatient Clinic of the Department of Rheuma-
tology, Physical Medicine and rehabilitation, Sestre Milosrdnice
University Hospital in Zagreb (Croatia) were included in this study.
They met the criteria of the American College of Rheumatology
(ACR) for the deﬁnition and classiﬁcation of knee OA. Patients
ought to have experienced knee pain for at least 14 days in the
past 30 days before the beginning of the study, with pain intensity
above 30 mm on the 100 mm visual analogue scale (VAS) and
Kellgren-Lawrence scale grade 2 or 3 on x-ray. Average duration
of the symptoms was 10.57±17.64 months. During the study, the
patients were allowed to be on a steady dose of pain-killers and/or
non-steroidal anti-inﬂammatory drugs (NSAIDs) if taken before,
while paracetamol could be used as an escape medication in a
dose up to 2 g per day for not more than 5 consecutive days.
The patients were randomly assigned into two groups: therapeutic
group in which PEMF was administered (intensity 6 mT; frequency
12 Hz) and placebo group where the machine was turned off. Each
patient received a total of 20 treatments that were administered for
30 minutes on 5 week days (with a weekend break). In addition,
all patients were performing isometric exercises for quadriceps
muscle strengthening, on daily basis. Symptoms of knee OA were
assessed by the WOMAC OA Index, a questionnaire addressing
severity of joint pain (5 questions), stiffness (2 questions) and
limitation of physical function (17 questions). Patients fulﬁlled the
questionnaire before the therapy, at the end of the therapy and
one month after the therapy was ﬁnished. Data were analyzed
by SPSS statistical program version 11.5. Apart from descriptive
statistics, t-test and one-way ANOVA were used. The level of
signiﬁcance was set at p<0.05.
Results: A total of 56 patients completed the study: 33 in the
group that received PEMFs and 23 in the group that received
placebo. There was no signiﬁcant difference between the thera-
peutic and control group regarding age, body mass index (BMI),
duration of symptoms and WOMAC OA Index. In both groups,
there was improvement in WOMAC overall scores at the end of
therapy (therapeutic group: t=2,509, df=32, p<0,01; control group:
t=3,164, df=22, p<0,01) as well as during post-treatment follow-up
(therapeutic group: t=3,384, df=28, p<0,01; control group: t=2,764,
df=22, p<0,01). But, no signiﬁcant difference between the groups
was observed at the end of therapy (F=1,134, df=55, p>0,05) and
during follow-up (F=0,003; df=55, p>0,05). Also, no statistically
signiﬁcant differences between the groups were found in WOMAC
subscales of pain (F=0,458, df=55, p>0,05), stiffness (F=0,083,
df=55, p>0,05) and physical function (F=1,145, df=55, p>0,05).
No adverse side-effects were observed during the administration
of PEMFs.
Conclusions: In our sample of patients with knee OA, PEMFs
showed no effect on improvement in activities of daily living, pain
and stiffness measured by WOMAC OA Index. The study was
limited by its small sample size. Further studies with a larger
number of patients are needed to determine the possible clinical
effect of PEMFs in patients with OA.
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CHANNA STRIATUS EXTRACT SUPPLEMENTATION
SIGNIFICANTLY INCREASED PROTEIN GENE PRODUCT
9.5-IMMUNOREACTIVE NERVE FIBRES COMPARED TO
ZINGIBER OFFICINALE EXTRACT IN COLLAGENASE
INDUCED OSTEAOARTHRITIS
S. Ganabadi
Universiti Putra Malaysia, Serdang, Selangor, Malaysia
Purpose: Channa striatus and Zingiber ofﬁcinale are two natu-
ral remedies that can be useful in treating osteoarthritis. The
aim of this study is to compare the protein gene related
9.5-immunoreactivity in the synovial membrane of collagenase
induced osteoarthritis between Zingiber ofﬁcinale extracts and
Channa striatus extract supplementation.
Methods: Osteoarthritis was induced in 30 adult male Sprague
Dawley rat by an intra-articular injection of 50μl of 4mg/ml collage-
nase into the right stiﬂe joint at D1 and D4. The rats were fed rat
pellet and water ad libitum. The rats were divided into three groups:
i. Group 1 is the control group and received saline, ii. Group 2
received 15ml/kg Channa striatus (CS) extract and iii. Group 3
received 15ml/kg of Zingiber ofﬁcinale (ZO) extract. Channa stria-
tus and Zingiber ofﬁcinale extracts were prepared according to the
methods previously described. The saline and extracts were fed
orally using feeding tube from D7 to D28. At D29 the rats were
sacriﬁced and synovial membrane sample were processed for im-
munohistochemistry. The ﬁxed samples were frozen in isopentane,
cooled in liquid Nitrogen and sectioned at 6μm. The sections were
dehydrated in ethanol, rinsed in 0.1M phosphate buffered saline,
then incubated in primary antisera against PGP 9.5 for 24 hours
at 4°C. Sections were then incubated in secondary antiserum (1
hour) followed by staining using HRP/DAB detection kit (Abcam,
USA).
Results: The density of PGP 9.5-immunoreactive nerve ﬁbres
(IR) in the synovial membrane was improved in the CS and
ZO group. The CS group showed signiﬁcantly highest number
(13.3±0.30) of PGP-IR nerve ﬁbres in the right (induced joint)
synovial membrane followed by the ZO (11.1±0.27) and the control
group (3.0±0.26). However, there were no signiﬁcant differences
between the synovial membranes in the contra-lateral (left) joints
(Table 1). When compared the PGP 9.5-immunoreactivity between
the right and left synovial membrane, there were no signiﬁcant
difference in the CS group but the differences were signiﬁcant in
the ZO and control group.
The IR nerve ﬁbres were abundant in the subintimal layer (Fig. 2)
and in the CS and ZO group these ﬁbres were found to be
penetrating between synoviocytes in the intimal layer (Fig. 1).
These were not found in the control group. Apart from this, the
Figure 1. PGP 9.5 immunoreactive
nerve ﬁbres (arrowheads) in the intimal
layer of synovial membrane from colla-
genase induced osteoarthritis treated
with Channa striatus extract. The
nerve ﬁbres were penetrating between
the synoviocytes (arrows).
Figure 2. PGP 9.5 immunoreactive
nerve ﬁbres (arrowhead) in the subin-
timal layer of synovial membrane
from collagenase induced osteoarthri-
tis treated with Channa striatus extract.
The nerve ﬁbres surround the blood
vessel (arrow).
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Table 1. Mean (± se) number of PGP 9.5-IR nerve ﬁbres in saline, CS & ZO
treated synovial membrane
Treatment L - Non-induced (n=10) R - Induced (n=10)
Saline (n=10) 12.6±0.44ax 3.0±0.26bz
ZO (n=10) 12.2±0.38ax 11.1±0.27by
CS (n=10) 12.7±0.32ax 13.3±0.30ax
synovial membrane from the control group was heavily inﬁltrated
with inﬂammatory cells and blood vessels were abundantly found
in the subintimal layer. In contrast, synovial membrane from the
CS and ZO group had mild inﬁltration of inﬂammatory cells with
fewer blood vessels.
Conclusions: Inﬂammatory changes in the synovial membrane
from the experimentally induced joints were reduced following
supplementation of CS and ZO extracts. This was evidenced by
the histological changes. The signiﬁcant increase in the PGP 9.5
immunoreactive nerve ﬁbres in CS and ZO group shows that
these extracts have anti-inﬂammatory properties. Apart from this
CS signiﬁcantly increases the PGP 9.5-immunoreactivity with huge
reduction of inﬂammatory cells compared to ZO. This indicates that
the active component in CS plays a major role in reducing the
inﬂammatory cells and increasing the nerve ﬁbres. Therefore, CS




CARTILAGE INFLAMMATION AND DEGRADATION
PROVIDED BY A BIOLOGICAL EXTRACT OF MENTHA
SPICATA
W. Pearson, R. Fletcher, L. Kott, M. Hurtig
Univ. of Guelph, Guelph, ON, Canada
Purpose: The purpose of the current study was to assess the
anti-inﬂammatory and/or chondroprotective properties of Mentha
spicata (MS), purpose-bred at the University of Guelph to express
high levels of rosmarinic acid (RA), in LPS-stimulated cartilage
explants.
Methods: RA content in MS leaves was determined by HPLC.
MS was added to simulated gastric ﬂuid and simulated intestinal
ﬂuid and incubated at 37°C (7% CO2) for a total of 4 hours.
Subsequently, pH was adjusted to 7.4 and liver microsomes from
rat and NADPH were added in order to mimic metabolism of
secondary plant metabolites by the liver and incubated for an
additional 30 minutes. The resulting mixture was ultraﬁltered (50
kDa) and an aliquot analyzed for RA and its primary hepatic
metabolites (m-coumaric acid, caffeic acid, methyl rosmarinic acid
and ferulic acid). A ‘blank’ simulated digest was made using the
identical methodology but without including any MS.
Cartilage explants (4mm diameter) were excised from the articu-
lating surface of the intercarpal joint of 11 healthy pigs using a
sterile 4mm dermal biopsy tool. Explants were cultured for a total
of 96 h. Media (1000 μL) was removed from each well every 24
h. For the ﬁrst 48 h (pre-stimulation), media samples were dis-
carded. During the ﬁnal 48 h (stimulation) samples were collected
into sterile microcentrifuge tubes containing 10μg indomethacin in
DMSO.
Tissue from each animal was subjected to treatment with each
dose of MS both with and without lipopolysaccharide (LPS) stim-
ulation. For the ﬁrst 24 h of culture, tissue culture media (TCM)
contained no MS or LPS. From 24 - 96 h, TCM contained MS [0
(ie. ‘blank’), 8, 40, 80, 240, 400 μg/mL]. For the ﬁnal 48 h, explants
were exposed to an inﬂammatory stimulus (LPS; 0 or 3 μg/mL)
in order to produce an inﬂammatory state in vitro. Samples were
analyzed for PGE2(ELISA), IL-1 (ELISA), GAG (DMB), and NO
(Griess Reaction). Data were analyzed using 2-way repeated mea-
sures ANOVA with respect to treatment and time. One-way RM
ANOVA was used to detect changes in dependent variables over
time within treatments. When a signiﬁcant F-ratio was obtained,
the Holm-Sidak post-hoc test was used to detect signiﬁcantly
different means. Signiﬁcance was accepted when p<0.05.
Results: RA content of the dry leaves was 8.0% w/w. RA con-
centration in the biological extract was 49.3 μg/mL. Caffeic acid,
ferulic acid, methyl RA and m-coumaric acid were identiﬁed in the
biological extract, but were not identiﬁed in the undigested leaves.
MS inhibited LPS-induced PGE2 and NO at all doses tested. LPS-
induced GAG release from explants at a dose of 80 μg/mL, but
not at the lower or higher doses. LPS-induced IL-1 production was
not affected by MS.
Conclusions: It is concluded that MS is an effective inhibitor of
LPS-induced inﬂammation in porcine cartilage explants; this effect
may be due to its high RA content. The relative contributions of
RA and hepatic metabolites of RA are not known and are currently
under investigation.
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MONTELUKAST SODIUM AS A TREATMENT FOR
EXPERIMENTAL OSTEOARTHRITIS IN MICE
P.J. Fanning, M.E. Walcott, S.L. O’Connell, K. Basil, J.A. Silva,
J.K. Lange, J.J. Wixted, A. Mason-Savas, D.C. Ayers
Univ. of Massachusetts Med. Sch., Worcester, MA
Purpose: Osteoarthritis (OA) is the most common form of arthri-
tis, worldwide. The underlying causes of the disease are unknown
however, the focal destruction of cartilage matrix and sclerosis
of underlying bone are thought to be the two predominant fac-
tors involved in progression of osteoarthritic disease. The most
effective treatment of OA remains the surgical removal and total
replacement of the joint (TJR) in later stages of OA. Currently,
no FDA-approved pharmacologic treatment of OA exists, particu-
larly with regard to agents that interfere with the primary structural
changes to cartilage and bone. The aims of the current study were
to test one such disease-modifying OA drug (DMOAD) candidate,
montelukast sodium in a preclinical mouse model of OA. Outcome
measures were histological scoring methods performed on mul-
tiple sections in untreated- vs. montelukast-treated OA mice to
assess potential chondroprotection and structure-modifying bone
effects offered by montelukast.
Methods: The right knees of 10 week old 129S6/SvEv male
mice were surgically induced to OA using the destabilization of
the medial meniscus (DMM). Mice were treated with montelukast
(1.5mg/Kg; qam) or carrier alone via direct intragastric delivery.
After 28 days, all knees were harvested intact & histologically
processed into 6 μm coronal sections yielding 15-20 sections per
knee. Sections were stained (Safranin-O) and scored by 3 blinded
observers using a modiﬁcation of an osteoarthritis scoring system.
Scores were analyzed using a mean maximal score representing
the highest scores for each knee, as well as a mean summed
score representing the sum of all scores within a single knee. All
scores were averaged across observers and all animals within -/+
treatment groups. Statistical signiﬁcance was analyzed using the
Kruskal-Wallis test.
Results: The mean maximal score for the montelukast-treated
OA mice (Fig. 1) was reduced by 57%. The mean summed score
(Fig. 2) which represents a combined score of OA grade and
stage was reduced by 43%. Direct morphometric measurements
of MKS-treated OA (Fig. 3) showed a 42% reduction in average
lesion area. Surprisingly, morphometric analysis of the subchon-
dral bone area (Fig. 3) showed a 9% (medial) and 8% (lateral)
decrease in OA-induced bony sclerosis with montelukast treat-
ment. This latter ﬁnding was unexpected but could represent an
